LASIK and Autoimmune / Chronic Conditions

Some autoimmune and chronic conditions affect wound healing or dryness. Eligibility is individualized, but many patients with well-managed conditions can safely undergo laser vision correction.

Why autoimmune conditions matter for LASIK

LASIK creates a corneal flap that must heal cleanly, and it temporarily disrupts the nerves that regulate tear production. Both of these processes depend on a properly functioning immune system. When the immune system is overactive (as in autoimmune disease), under-regulated, or suppressed by medication, the healing cascade can behave unpredictably. That does not automatically disqualify a patient, but it does mean the surgeon, the patient’s specialist, and often a cornea or dry-eye subspecialist need to coordinate before proceeding.

Specific conditions that require extra evaluation

Sjogren’s syndrome

Sjogren’s directly attacks moisture-producing glands, including the lacrimal (tear) glands. Patients already experience moderate to severe dry eye at baseline, and LASIK can worsen dryness for months. Many refractive surgeons consider active Sjogren’s a relative or absolute contraindication. Patients with mild, well-managed Sjogren’s whose Schirmer and tear break-up time tests are adequate may still be candidates, but PRK is often preferred because it avoids the flap-related nerve disruption that can intensify dryness.

Rheumatoid arthritis (RA)

RA can cause peripheral ulcerative keratitis and scleritis, both of which complicate corneal surgery. When the disease is in stable remission and no ocular inflammation has been present for at least six to twelve months, many surgeons will consider LASIK. A clearance letter from the treating rheumatologist documenting disease activity scores (such as DAS28) and current medications is standard practice.

Systemic lupus erythematosus (SLE / lupus)

Lupus can affect almost any tissue, including the cornea, retina, and lacrimal system. Patients with lupus-related dry eye, retinal vasculitis, or active flares are typically not candidates. Those in sustained remission on stable therapy may be evaluated on a case-by-case basis, with close attention to anti-phospholipid antibody status (which can affect microvascular healing).

Crohn’s disease and inflammatory bowel disease

While Crohn’s and ulcerative colitis primarily affect the gut, extra-intestinal manifestations include uveitis, episcleritis, and dry eye. These ocular complications should be screened for and quiescent before refractive surgery is considered. Patients on biologic therapy (see medication section below) also need specific evaluation.

Multiple sclerosis (MS)

MS can cause optic neuritis, which may transiently or permanently affect visual acuity. LASIK does not treat or worsen optic neuritis, but surgeons need to confirm that the patient’s baseline visual complaints are refractive, not neurological. A stable neurological exam and clearance from the treating neurologist are essential. Patients who have had recent optic neuritis episodes (within the prior 12 months) are generally asked to wait.

Other conditions

Thyroid eye disease (Graves’), type 1 diabetes with autoimmune overlap, psoriatic arthritis, ankylosing spondylitis, and sarcoidosis all warrant individualized evaluation. The common thread is disease stability, absence of active ocular inflammation, and a medication regimen that does not prohibit healing.

Medication considerations

Immunosuppressants

Drugs such as methotrexate, azathioprine, mycophenolate, and cyclosporine (systemic) modulate the immune response. While they reduce harmful inflammation, they can also slow wound healing and increase infection susceptibility. Most surgeons do not require patients to stop these medications for LASIK, but they do factor the drug and dose into their risk assessment. Abruptly stopping immunosuppressive therapy to accommodate surgery can trigger a disease flare, which is far more dangerous than the theoretical healing delay.

Biologic agents

TNF-alpha inhibitors (adalimumab, infliximab, etanercept), IL-6 inhibitors (tocilizumab), and JAK inhibitors (tofacitinib, upadacitinib) are increasingly common. These drugs can impair corneal epithelial migration and immune surveillance against infection. Some surgeons prefer to schedule surgery midway between biologic doses so that drug levels are not at their peak, though evidence-based guidelines on exact timing are limited. The prescribing specialist should be involved in this decision.

Corticosteroids

Chronic oral corticosteroids raise intraocular pressure (IOP) in susceptible individuals and can thin the cornea over time. Patients on long-term prednisone or equivalent should have IOP and pachymetry (corneal thickness) carefully monitored. Topical steroid drops are a routine part of post-LASIK care, so steroid responders need closer IOP follow-up during recovery.

Hydroxychloroquine (Plaquenil)

Commonly used in lupus and RA, hydroxychloroquine is generally not a concern for corneal surgery. However, long-term use can cause retinal toxicity, so a baseline retinal exam is advisable before any elective eye procedure.

Wound healing concerns

The LASIK flap typically re-adheres within the first 24 hours and stabilizes over weeks to months. In immunocompromised patients, this timeline can be slower, and the risk of diffuse lamellar keratitis (DLK, also known as “sands of the Sahara”) may be elevated. DLK is an inflammatory reaction under the flap that, if caught early, responds well to intensive steroid drops. Surgeons managing autoimmune patients tend to schedule more frequent early follow-up visits (day 1, day 3, and week 1 rather than just day 1 and month 1) to catch any healing irregularities promptly.

Epithelial ingrowth, where surface cells migrate under the flap edge, is another complication that can be more common when healing is atypical. It is treatable but reinforces the need for close post-operative monitoring.

When PRK may be safer than LASIK

PRK (photorefractive keratectomy) removes the corneal epithelium rather than creating a flap. This eliminates flap-related complications entirely: no risk of DLK, no flap dislocation, and no epithelial ingrowth. The trade-off is a longer visual recovery (typically one to two weeks of blurry vision versus one day with LASIK) and more post-operative discomfort.

For patients with autoimmune conditions, PRK is often the preferred procedure because:

• It avoids severing the corneal nerve plexus as extensively as a flap does, which can be better for patients already prone to dry eye.
• There is no flap interface where inflammatory cells can accumulate.
• Healing, while slower, is more straightforward to monitor since it occurs on the surface.

SMILE (small incision lenticule extraction) is another flapless alternative that some surgeons consider, though long-term data in autoimmune populations is more limited than for PRK.

Specialist coordination: what a good process looks like

1. Initial refractive consultation. The surgeon performs topography, pachymetry, tear film evaluation, and a thorough ocular and systemic history.
2. Specialist clearance. The surgeon sends a specific request to the rheumatologist, neurologist, gastroenterologist, or other specialist documenting what information is needed: disease activity, medication stability, any history of ocular involvement, and an opinion on surgical timing.
3. Ocular surface optimization. If dry eye or meibomian gland dysfunction is present, a treatment protocol (warm compresses, omega-3 supplementation, prescription drops such as cyclosporine or lifitegrast, or in-office treatments) is started weeks to months before surgery.
4. Shared decision-making. The patient, surgeon, and specialist agree on a procedure (LASIK, PRK, or an alternative), timing relative to medication dosing, and a post-operative monitoring plan.
5. Enhanced post-operative schedule. More frequent visits in the first two weeks, with clear instructions on when to call if symptoms suggest inflammation or infection.

Questions to bring to your consultation

• Has my autoimmune condition been stable long enough for you to feel comfortable proceeding?
• Do I need to adjust the timing of my biologic or immunosuppressant dose around surgery?
• Would you recommend PRK over LASIK given my specific condition and tear film?
• What is your protocol if I develop DLK or another inflammatory complication?
• How will you coordinate with my rheumatologist / neurologist / other specialist?

Related guides

• LASIK Candidacy Checklist: How Surgeons Decide
• Managing Dry Eye Before and After LASIK
• LASIK vs PRK vs SMILE: Which Procedure Fits Your Eyes?
• LASIK Risks, Complications, and How Surgeons Mitigate Them
• LASIK for Diabetics: Eligibility and Healing Tips

Sources

• Moshirfar M, et al. “LASIK in patients with autoimmune diseases: a review.” Journal of Refractive Surgery. 2020.
• Alio JL, Soria FA. “Refractive surgery in systemic and autoimmune disease.” Survey of Ophthalmology. 2019.
• American Academy of Ophthalmology. “Refractive Errors & Refractive Surgery Preferred Practice Pattern.” 2023.
• Randleman JB, et al. “Risk assessment for ectasia after corneal refractive surgery.” Ophthalmology. 2008.
• Fogla R, Rao SK. “Corneal refractive surgery in patients with connective tissue disorders.” Indian Journal of Ophthalmology. 2019.